Skip to main content

02 October 2020

Redefining AAV Manufacturing: The Time Is Now

Ryan Cawood

Tutorial/GEN News/02 October 2020/Issue Vol. 40 No. 10

View More


Until very recently, adeno-associated virus (AAV) had an excellent safety record as a viral vector for gene therapies, which goes a long way to explain its widespread use in this capacity. However, the question of immunogenicity and particle toxicity—especially at high doses of AAV—is rearing its ugly head.

View the paper in full here.